Our Leadership

j-karrisJames Karis

Chief Executive Officer

James is a life sciences and healthcare industry executive with over 35 years of experience in the pharmaceutical, healthcare services, technology and medical device industries. A proven entrepreneur he is also an experienced Board member for public and private companies with extensive experience in corporate strategy, M&A and all aspects of company financing. He is currently, Chief Executive Officer of privately held MAPI Group, a company focused on conducting late phase studies as well as providing regulatory and reimbursement support to the pharmaceutical and device industries. James has previously held senior management and executive roles at CollabRx, Entelos, Inc., PAREXEL International, Pharmaco International and Baxter International. He has a B.S in Management and Economics from Purdue University and a M.A. in Applied Economics from The American University.


Client Services & Operations

n_pageNigel Page

Real World Evidence

Nigel Page currently serves as President and Chief Operating Officer and is responsible for the global operations of the real world evidence business of Mapi.
Mr. Page has more than 30 years of experience in the Pharmaceutical and CRO industries in roles encompassing clinical research, regulatory affairs, sales & marketing, quality improvement, IT, M&A and General/Executive Management. He has worked in the UK, USA, Germany and, most recently, France having joined the Mapi Group as CEO of their Late Phase business, Mapi RWE Europe, towards the end of 2010.

Mr. Page has particular interests in the development of businesses in global environments; leading change; the integration of organization, process and technology to provide leading capabilities and developing high performance teams.

 

terrimadisonTerri Madison

Real World Strategy & Analytics

Dr. Madison is an epidemiologist with over 25 years of experience using evidence-based science to reinforce the risk-benefit profile of biopharmaceutical products and optimize appropriate access.

Dr. Madison is an industry expert in epidemiology, drug safety, and risk management. Her comprehensive understanding of regulations and guidance documents, and broad knowledge of existing programs across a variety of products and product classes, enables her to provide evidence-based strategic advice that synergizes risk management and safety strategy with the overall value-driven commercial strategy to maximize appropriate patient access and product risk-benefit.

Dr. Madison’s core research interests and expertise include pregnancy surveillance, risk management, design and conduct of observational cancer studies, and effects of race and socioeconomic status on disparities in health outcomes. Her work in these and other areas has been published in peer-reviewed journals and she has authored several book chapters.

 

stuartwrightStuart Wright

Strategic Regulatory Services

Mr. Wright is a proven leader with 30 years of experience in the pharmaceutical and specialty chemical industries. He has specific expertise in design and implementation of business systems, operations management, process improvement, and cGMP compliance management. He has a solid chemistry background, serving as the foundation for talents demonstrated in quality assurance, process validation, and research/development. Mr. Wright has worked as a CMC Regulatory Consultant for eight years and before that was employed by both large and small pharmaceutical companies in North America and Europe. His background includes experience with innovative and generic companies and with many different dosage forms.

Presently, Mr. Wright under Mapi leads a team of 90 Regulatory, Pharmacovigilance, CMC and Quality professionals that work with regional regulatory specialists located around the world.

 

a_baylesAna Bayles

Linguistic Validation

Ms. Bayles is an operation executive with an extensive knowledge of 20 years in Life Science; principal expertise in multiple functional areas including management of global teams, Quality and Compliance, Logistics, Laboratory areas.

She is committed to Quality and Operational Excellence with solid interpersonal skills and a proven track record of global achievements.  Ms. Bayles’ has proven leadership skills and business acumen with a reputation as a catalyst for change. Her ability to work well in cross-functional environments with sound negotiation and proven solving skills, has been confirmed throughout her portfolio of work.

Ana has a medical degree in Biology and started her career by working in hospitals, then she led Europe Laboratory Operations in Central Laboratory (MDS) dedicated to clinical trials. Prior to joining Mapi she was the Director of the Technical Platform at NOVESCIA.
Ana joined Mapi in July 2013 as Operations Director of the Language Services Business Unit and is currently Global Director Language Services at Mapi.

 

w-maierWill Maier

Patient-Centered Sciences

Mapi’s Chief Scientific Officer, Dr. Will Maier provides scientific leadership to Mapi’s research and consulting services across a range of scientific areas. Dr. Maier has more than 20 years of drug development and commercialization experience. He served as Senior Director of Epidemiology at GlaxoSmithKline and Elan Pharmaceuticals and led research groups conducting observational research to support reimbursement, marketing and drug safety investigations of pharmaceuticals. Dr. Maier is a member of the EMA’s European Network of Centres for Pharmacoepidemiology and Pharmacovigilance.

Scientific Leaders

r_christensenRon Christensen

Chief Medical Officer

Ronald Christensen, M.D., contributes his thought leadership to the industry by participating in key working groups and workshops. His guidance and knowledge of key indications—including Cystic Fibrosis, Crohn’s Disease, and rare disease areas including Cushing’s syndrome and Duchenne’s Muscular—is a true asset in our experience.

At Mapi, Dr. Christensen has continued his involvement as a thought leader. He was invited to present at the 5th Annual International Conference on Rare Diseases and Orphan Drugs (ICORD). In 2009, he was invited to join an NIH Working Group to develop a standardized Global Rare Disease Registry (GRDR).

In 2016, Dr. Christensen was invited to serve as a member of the International Rare Diseases Research Consortium (IRDiRC) Task Force, a group working to achieve two main objectives by 2020: to deliver 200 new therapies for rare diseases, and the means to diagnose most rare diseases.

 

w-maierWill Maier

Chief Scientific officer

Mapi’s Chief Scientific Officer, Dr. Will Maier provides scientific leadership to Mapi’s research and consulting services across a range of scientific areas. Dr. Maier has more than 20 years of drug development and commercialization experience. He served as Senior Director of Epidemiology at GlaxoSmithKline and Elan Pharmaceuticals and led research groups conducting observational research to support reimbursement, marketing and drug safety investigations of pharmaceuticals. Dr. Maier is a member of the EMA’s European Network of Centres for Pharmacoepidemiology and Pharmacovigilance.

Shared Services

a_blazeiAlan Blazei

Chief Scientific Officer

Alan Blazei is a senior financial executive offering over 30 years of finance, accounting, treasury management, and global business development experience. He’s worked with companies like the industry leading Maxxim Medical and the Fortune 500 firm Dayton-Hudson, as well as public accounting and high-tech entrepreneurial start-ups. A strong leader and visionary, Mr. Blazei is often recognized as the CEO’s “right-hand man" and is particularly comfortable operating in international arenas, structuring agreements and transitioning assimilated assets. Mr. Blazei was featured in the December 1998 issue of CFO Magazine.